JP2020511459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511459A5 JP2020511459A5 JP2019550175A JP2019550175A JP2020511459A5 JP 2020511459 A5 JP2020511459 A5 JP 2020511459A5 JP 2019550175 A JP2019550175 A JP 2019550175A JP 2019550175 A JP2019550175 A JP 2019550175A JP 2020511459 A5 JP2020511459 A5 JP 2020511459A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- active agent
- item
- items
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 278
- 239000013543 active substance Substances 0.000 claims description 134
- 238000000034 method Methods 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 210000003734 kidney Anatomy 0.000 claims description 16
- 210000000845 cartilage Anatomy 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 239000002872 contrast media Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 102000005600 Cathepsins Human genes 0.000 claims description 3
- 108010084457 Cathepsins Proteins 0.000 claims description 3
- 102000053187 Glucuronidase Human genes 0.000 claims description 3
- 108010060309 Glucuronidase Proteins 0.000 claims description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- HUUSXLKCTQDPGL-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea Chemical compound CC(C)(O)C1=COC(S(=O)(=O)NC(=O)NC=2C=3CCCC=3C=C3CCCC3=2)=C1 HUUSXLKCTQDPGL-UHFFFAOYSA-N 0.000 claims 1
- 102000004171 Cathepsin K Human genes 0.000 claims 1
- 108090000625 Cathepsin K Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 239000004012 Tofacitinib Substances 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000000746 body region Anatomy 0.000 claims 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims 1
- 229940043256 calcium pyrophosphate Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000003977 fibroblast growth factor 18 Human genes 0.000 claims 1
- 108090000370 fibroblast growth factor 18 Proteins 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 229960001350 tofacitinib Drugs 0.000 claims 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 230000008685 targeting Effects 0.000 description 11
- 230000001575 pathological effect Effects 0.000 description 6
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 208000034693 Laceration Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- -1 thrombins Proteins 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229940127343 Potassium Channel Agonists Drugs 0.000 description 1
- 229940127316 Potassium Channel Antagonists Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229940127505 Sodium Channel Antagonists Drugs 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000801 calcium channel stimulating agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000003378 sodium channel stimulating agent Substances 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023078678A JP2023099623A (ja) | 2017-03-16 | 2023-05-11 | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472485P | 2017-03-16 | 2017-03-16 | |
| US62/472,485 | 2017-03-16 | ||
| PCT/US2018/023006 WO2018170480A1 (en) | 2017-03-16 | 2018-03-16 | Cartilage-homing peptide conjugates and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078678A Division JP2023099623A (ja) | 2017-03-16 | 2023-05-11 | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511459A JP2020511459A (ja) | 2020-04-16 |
| JP2020511459A5 true JP2020511459A5 (enExample) | 2021-04-15 |
| JP7280193B2 JP7280193B2 (ja) | 2023-05-23 |
Family
ID=63523337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550175A Active JP7280193B2 (ja) | 2017-03-16 | 2018-03-16 | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
| JP2023078678A Pending JP2023099623A (ja) | 2017-03-16 | 2023-05-11 | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078678A Pending JP2023099623A (ja) | 2017-03-16 | 2023-05-11 | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11013814B2 (enExample) |
| EP (1) | EP3595699A4 (enExample) |
| JP (2) | JP7280193B2 (enExample) |
| CN (1) | CN110475565A (enExample) |
| AU (1) | AU2018236465A1 (enExample) |
| CA (1) | CA3056421A1 (enExample) |
| WO (1) | WO2018170480A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| CN108135970B (zh) | 2015-09-09 | 2023-09-01 | 弗莱德哈钦森癌症中心 | 软骨归巢肽 |
| AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
| EP3595699A4 (en) | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| CA3064436A1 (en) | 2017-06-15 | 2018-12-20 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
| AU2018388583A1 (en) | 2017-12-19 | 2020-06-11 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| EP3773668A4 (en) * | 2018-03-16 | 2022-10-19 | Blaze Bioscience, Inc. | Truncated cartilage-homing peptides and peptide complexes and methods of use thereof |
| WO2019209662A1 (en) * | 2018-04-23 | 2019-10-31 | Fred Hutchinson Cancer Research Center | Conjugates of cartilage-homing peptides |
| WO2020112962A1 (en) * | 2018-11-30 | 2020-06-04 | Renibus Therapeutics, Inc. | Methods for treating renal injury by therapeutically upregulating p21 |
| US20220089663A1 (en) * | 2019-01-18 | 2022-03-24 | Memorial Sloan Kettering Cancer Center | PROTEINS AND FLUOROPHORE-CONTAINING COMPOUNDS SELECTIVE FOR NaV1.7 |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| CA3205538A1 (en) * | 2021-01-19 | 2022-07-28 | Han XIAO | Bone-specific delivery of polypeptides |
| CN113577246B (zh) * | 2021-08-02 | 2023-11-03 | 赛克赛斯生物科技股份有限公司 | 一种预防瘢痕粘连的组合物、术后防粘连材料及应用 |
| WO2024173795A1 (en) * | 2023-02-17 | 2024-08-22 | California Institute Of Technology | Activatable drug conjugates and therapeutic applications thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2269060C (en) | 1996-10-17 | 2009-04-07 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| WO2001053342A1 (en) | 2000-01-21 | 2001-07-26 | The Burnham Institute | Chimeric prostate-homing peptides with pro-apoptotic activity |
| JP2005511017A (ja) | 2001-09-05 | 2005-04-28 | キングス カレッジ ロンドン | ホーミングペプチド |
| WO2003082196A2 (en) | 2002-03-26 | 2003-10-09 | The General Hospital Corporation | Combination therapy using trefoil peptides |
| US20060088899A1 (en) | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| ZA200505393B (en) * | 2002-12-26 | 2007-03-28 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| EP1812082B1 (en) * | 2004-10-21 | 2013-08-14 | IGF Oncology, LLC | Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer |
| FR2877946B1 (fr) | 2004-11-12 | 2011-02-11 | Commissariat Energie Atomique | Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet |
| CN101583370A (zh) | 2005-09-27 | 2009-11-18 | 阿穆尼克斯公司 | 蛋白质药物及其用途 |
| US7592009B2 (en) | 2006-10-10 | 2009-09-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Polypeptide ligands for targeting cartilage and methods of use thereof |
| JP5463013B2 (ja) | 2007-06-19 | 2014-04-09 | 国立大学法人 岡山大学 | 軟骨マーカー |
| CN101918041A (zh) | 2007-10-12 | 2010-12-15 | 超分子有限公司 | 用于肿瘤诊断和治疗的氯毒素剂的系统性给药 |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| US20130280281A1 (en) | 2010-07-02 | 2013-10-24 | Jean-Paul Castaigne | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| AU2011326164B2 (en) | 2010-11-08 | 2016-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| WO2013078250A2 (en) | 2011-11-22 | 2013-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides that bind alpha-v-beta-6 integrin |
| US10426850B2 (en) | 2011-11-22 | 2019-10-01 | The Johns Hopkins University | Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use |
| JP5724937B2 (ja) | 2012-04-23 | 2015-05-27 | ニプロ株式会社 | 腎臓集積性を示すペプチド、製剤 |
| CN104884473B (zh) * | 2012-05-22 | 2019-12-03 | 百时美施贵宝公司 | Il-17a/f il-23双特异性抗体及其应用 |
| WO2014004465A1 (en) * | 2012-06-25 | 2014-01-03 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| WO2014063012A1 (en) | 2012-10-19 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| US20140179560A1 (en) | 2012-12-10 | 2014-06-26 | Fred Hutchinson Cancer Research Center | Drug discovery methods and platforms |
| SI2994153T1 (sl) | 2013-05-07 | 2018-12-31 | Merck Patent Gmbh | Peptidi in konjugati peptid-učinkovina za renalno ciljanje |
| JP2016528174A (ja) * | 2013-05-31 | 2016-09-15 | セルリアン・ファーマ・インコーポレイテッド | 治療的送達用のシクロデキストリンベースのポリマー |
| CA2916725A1 (en) | 2013-07-22 | 2015-01-29 | Kineta One, Llc | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof |
| US20170050988A1 (en) | 2013-11-25 | 2017-02-23 | Sanofi | Dotam derivatives for therapeutic use |
| US20160338967A1 (en) * | 2013-12-23 | 2016-11-24 | Kineta One, Llc | Sustained release depot formulations of therapeutic proteins, and uses thereof |
| CN111620940A (zh) | 2014-05-21 | 2020-09-04 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| CN107405388A (zh) | 2015-01-08 | 2017-11-28 | 衣阿华大学研究基金会 | 用于体内关节软骨再生的方法 |
| WO2016112208A2 (en) | 2015-01-09 | 2016-07-14 | Kineta One, Llp | Topical applications of kv1.3 channel blocking peptides to treat skin inflammation |
| WO2016118859A1 (en) | 2015-01-22 | 2016-07-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells comprising flip |
| BR112017027985A2 (pt) * | 2015-06-26 | 2018-08-28 | Hutchinson Fred Cancer Res | peptídeos terapêuticos e métodos de uso dos mesmos |
| CN106380521B (zh) | 2015-07-02 | 2020-12-29 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| CN108135970B (zh) | 2015-09-09 | 2023-09-01 | 弗莱德哈钦森癌症中心 | 软骨归巢肽 |
| WO2017100700A2 (en) | 2015-12-11 | 2017-06-15 | Fred Hutchinson Cancer Research Center | Peptides for renal therapy |
| CA3053242A1 (en) | 2016-02-19 | 2017-08-24 | Dignity Health | Antibody fusion protein and related compositions for targeting cancer |
| WO2018049285A1 (en) * | 2016-09-09 | 2018-03-15 | Fred Hutchinson Cancer Research Center | Stable peptides and methods of use thereof |
| WO2018119001A1 (en) | 2016-12-19 | 2018-06-28 | Fred Hutchinson Cancer Research Center | Peptide-antibody compositions and methods of use thereof |
| AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
| EP3595699A4 (en) | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| CA3064436A1 (en) | 2017-06-15 | 2018-12-20 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
-
2018
- 2018-03-16 EP EP18767105.2A patent/EP3595699A4/en not_active Withdrawn
- 2018-03-16 AU AU2018236465A patent/AU2018236465A1/en not_active Abandoned
- 2018-03-16 CN CN201880014833.XA patent/CN110475565A/zh active Pending
- 2018-03-16 CA CA3056421A patent/CA3056421A1/en active Pending
- 2018-03-16 JP JP2019550175A patent/JP7280193B2/ja active Active
- 2018-03-16 WO PCT/US2018/023006 patent/WO2018170480A1/en not_active Ceased
- 2018-03-16 US US16/492,914 patent/US11013814B2/en not_active Expired - Fee Related
-
2021
- 2021-04-14 US US17/230,353 patent/US20210260205A1/en not_active Abandoned
-
2023
- 2023-05-11 JP JP2023078678A patent/JP2023099623A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511459A5 (enExample) | ||
| US11648290B2 (en) | Cartilage-homing peptides | |
| JP2018527348A5 (enExample) | ||
| JP5907999B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| JP4675028B2 (ja) | トリメチルロック型テトラパルテートプロドラッグ | |
| JP7280193B2 (ja) | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 | |
| KR102787208B1 (ko) | α4β7 인테그린 티오에테르 펩티드 길항제 | |
| AU2017322523A1 (en) | Stable peptides and methods of use thereof | |
| ES2804476T3 (es) | Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado contra el transportador NaPI2B | |
| TW201106964A (en) | A motilin-link peptide compound offering absorptivity via mucous administration | |
| CN112778403A (zh) | 环肽类抗肿瘤活性化合物及其制备方法与应用 | |
| ES2324027T3 (es) | Peptidos sinteticos y usos de los mismos para la prevencion y terapia en la invasion del cancer y la metastasis. | |
| US20210252159A1 (en) | Conjugates of cartilage-homing peptides | |
| JPWO2019178573A5 (enExample) | ||
| WO2024057793A1 (ja) | 癌転移を抑制するシトルリン化ペプチド | |
| WO2025097674A1 (zh) | 一种新型pace4抑制剂及其在抗骨关节炎中的应用 | |
| TW202542175A (zh) | 人類介白素(il)-17細胞激素結合肽 |